An experimental single-dose therapy has shown the capability to reduce low-density lipoprotein, commonly known as bad cholesterol, by up to 62% in early clinical trials. The novel treatment utilizes gene-editing technology to achieve long-lasting cholesterol reduction without requiring daily administration.
Significant Reductions in Clinical Studies
Results gathered across small trial cohorts, including research conducted in Cleveland, demonstrated that patients experienced sharp declines in bad cholesterol after receiving just one dose. In trial results, the single-time treatment successfully lowered cholesterol levels by up to 62%, with the effect persisting over extended observation periods.
A Non-Statin Approach to Cardiovascular Care
Unlike standard daily treatments such as statins, the experimental drug targets cholesterol regulation at the genetic level. Researchers designated the findings as a notable milestone in cardiovascular medicine, highlighting that a single administration could potentially manage cholesterol for years.
Additional clinical studies will be required to assess the long-term safety and broader efficacy of the drug before it can be submitted for regulatory approval and standard medical use.
